Bio-Techne Corp Files Q2 2025 10-Q
Ticker: TECH · Form: 10-Q · Filed: Feb 6, 2025 · CIK: 842023
| Field | Detail |
|---|---|
| Company | Bio-Techne Corp (TECH) |
| Form Type | 10-Q |
| Filed Date | Feb 6, 2025 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Bio-Techne's Q2 2025 10-Q is in. Check financials.
AI Summary
Bio-Techne Corp filed its 10-Q for the period ending December 31, 2024. The company, incorporated in Minnesota, operates in the biological products sector. Its fiscal year ends on June 30th, and this filing covers the second quarter of its 2025 fiscal year.
Why It Matters
This filing provides investors with an update on Bio-Techne's financial performance and operational status for the second quarter of fiscal year 2025.
Risk Assessment
Risk Level: low — This is a standard quarterly financial filing with no immediate red flags.
Key Numbers
- 20241231 — Fiscal Period End (Indicates the end of the reporting quarter for financial statements.)
- 20250206 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- BIO-TECHNE Corp (company) — Filer
- 20241231 (date) — Reporting period end date
- 20250206 (date) — Filing date
- MINNEAPOLIS (location) — Company headquarters city
- MN (location) — Company headquarters state
FAQ
What is the primary business of Bio-Techne Corp?
Bio-Techne Corp operates in the sector of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
When does Bio-Techne Corp's fiscal year end?
Bio-Techne Corp's fiscal year ends on June 30th.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending December 31, 2024, which corresponds to the second quarter of their fiscal year 2025.
Where is Bio-Techne Corp headquartered?
Bio-Techne Corp is headquartered in Minneapolis, MN.
What is the SEC Act under which this filing is made?
This filing is made under the 1934 Act.
Filing Stats: 4,460 words · 18 min read · ~15 pages · Grade level 17.2 · Accepted 2025-02-06 16:30:29
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value TECH The NASDAQ Stock Mar
Filing Documents
- tech-20241231x10q.htm (10-Q) — 2598KB
- tech-20241231xex31d1.htm (EX-31.1) — 9KB
- tech-20241231xex31d2.htm (EX-31.2) — 9KB
- tech-20241231xex32d1.htm (EX-32.1) — 5KB
- tech-20241231xex32d2.htm (EX-32.2) — 6KB
- 0001558370-25-000689.txt ( ) — 12569KB
- tech-20241231.xsd (EX-101.SCH) — 51KB
- tech-20241231_cal.xml (EX-101.CAL) — 79KB
- tech-20241231_def.xml (EX-101.DEF) — 212KB
- tech-20241231_lab.xml (EX-101.LAB) — 462KB
- tech-20241231_pre.xml (EX-101.PRE) — 396KB
- tech-20241231x10q_htm.xml (XML) — 3453KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited) 1 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 36 Item 4.
Controls and Procedures
Controls and Procedures 37
: OTHER INFORMATION
PART II: OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 37 Item 1A.
Risk Factors
Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38 Item 3. Defaults Upon Senior Securities 38 Item 4. Mine Safety Disclosures 38 Item 5. Other Information 38 Item 6. Exhibits 39
SIGNATURES
SIGNATURES 42 Table of Contents
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME Bio-Techne Corporation and Subsidiaries (in thousands, except per share data) (unaudited) Quarter Ended Six Months Ended December 31, December 31, 2024 2023 2024 2023 Net sales $ 297,031 $ 272,598 $ 586,489 $ 549,533 Cost of sales 103,145 96,011 209,586 187,755 Gross margin 193,886 176,587 376,903 361,778 Operating expenses: Selling, general and administrative 121,451 115,667 240,612 220,998 Research and development 25,016 22,916 48,885 46,914 Total operating expenses 146,467 138,583 289,497 267,912 Operating income 47,419 38,004 87,406 93,866 Other income (expense) ( 4,543 ) ( 4,617 ) ( 4,359 ) ( 10,921 ) Earnings before income taxes 42,876 33,387 83,047 82,945 Income taxes 7,986 5,922 14,557 4,486 Net earnings $ 34,890 $ 27,465 $ 68,490 $ 78,459 Other comprehensive income (loss): Foreign currency translation income (loss) ( 25,518 ) 18,025 ( 4,262 ) 6,423 Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 ( 45 ) ( 3,670 ) ( 3,072 ) ( 4,020 ) Other comprehensive income (loss) ( 25,563 ) 14,355 ( 7,334 ) 2,403 Comprehensive income $ 9,327 $ 41,820 $ 61,156 $ 80,862 Earnings per share: Basic $ 0.22 $ 0.17 $ 0.43 $ 0.50 Diluted $ 0.22 $ 0.17 $ 0.42 $ 0.49 Weighted average common shares outstanding: Basic 158,431 157,533 158,481 157,826 Diluted 160,626 160,060 161,353 161,001 See Notes to Condensed Consolidated Financial Statements. 1 Table of Contents CONDENSED CONSOLIDATED BALANCE SHEETS Bio-Techne Corporation and Subsidiaries (in thousands, except share and per share data) December 31, 2024 June 30, (unaudited) 2024 ASSETS Current assets: Cash and cash equiv